MBCI Stock Overview
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MabCure, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000016 |
| 52 Week High | US$0.009 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 1,500.00% |
| 3 Month Change | -84.00% |
| 1 Year Change | -92.00% |
| 3 Year Change | -99.61% |
| 5 Year Change | -98.55% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| MBCI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 1.0% |
| 1Y | -92.0% | 0.9% | 21.9% |
Return vs Industry: MBCI underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: MBCI underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| MBCI volatility | |
|---|---|
| MBCI Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MBCI's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MBCI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Jehu Thomas Hand | n/a |
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan.
MabCure, Inc. Fundamentals Summary
| MBCI fundamental statistics | |
|---|---|
| Market cap | US$12.50k |
| Earnings (TTM) | -US$12.26m |
| Revenue (TTM) | US$500.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs MBCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBCI income statement (TTM) | |
|---|---|
| Revenue | US$500.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$500.00k |
| Other Expenses | US$12.76m |
| Earnings | -US$12.26m |
Last Reported Earnings
Dec 31, 2011
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MBCI perform over the long term?
See historical performance and comparison